Attributable mortality of infections caused by carbapenem-resistant Enterobacterales : results from a prospective, multinational case-control-control matched cohorts study (EURECA)
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: To assess the mortality attributable to infections caused by carbapenem-resistant Enterobacterales (CRE) and to investigate the effect of clinical management on differences in observed outcomes in a multinational matched cohort study.
METHODS: A prospective matched-cohorts study (NCT02709408) was performed in 50 European hospitals from March 2016 to November 2018. The main outcome was 30-day mortality with an active post-discharge follow-up when applied. The CRE cohort included patients with complicated urinary tract infections, complicated intra-abdominal infections, pneumonia, or bacteraemia from other sources because of CRE. Two control cohorts were selected: patients with infection caused by carbapenem-susceptible Enterobacterales (CSE) and patients without infection. Matching criteria included type of infection for the CSE group, hospital ward of CRE detection, and duration of hospital admission up to CRE detection. Multivariable and stratified Cox regression was applied.
RESULTS: The cohorts included 235 patients with CRE infection, 235 patients with CSE infection, and 705 non-infected patients. The 30-day mortality (95% CI) was 23.8% (18.8-29.6), 10.6% (7.2-15.2), and 8.4% (6.5-10.6), respectively. The difference in 30-day mortality rates between patients with CRE infection when compared with patients with CSE infection was 13.2% (95% CI, 6.3-20.0), (HR, 2.57; 95% CI, 1.55-4.26; p < 0.001), and 15.4% (95% CI, 10.5-20.2) when compared with non-infected patients (HR, 3.85; 95% CI, 2.57-5.77; p < 0.001). The population attributable fraction for 30-day mortality for CRE vs. CSE was 19.28%, and for CRE vs. non-infected patients was 9.61%. After adjustment for baseline variables, the HRs for mortality were 1.87 (95% CI, 0.99-3.50; p 0.06) and 3.65 (95% CI, 2.29-5.82; p < 0.001), respectively. However, when treatment-related time-dependent variables were added, the HR of CRE vs. CSE reduced to 1.44 (95% CI, 0.78-2.67; p 0.24).
DISCUSSION: CRE infections are associated with significant attributable mortality and increased adjusted hazard of mortality when compared with CSE infections or patients without infection. Underlying patient characteristics and a delay in appropriate treatment play an important role in the CRE mortality.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 30(2024), 2 vom: 01. Jan., Seite 223-230 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paniagua-García, María [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimicrobial resistance |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 26.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2023.11.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367575264 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367575264 | ||
| 003 | DE-627 | ||
| 005 | 20240126232159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2023.11.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM367575264 | ||
| 035 | |a (NLM)38267096 | ||
| 035 | |a (PII)S1198-743X(23)00566-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paniagua-García, María |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Attributable mortality of infections caused by carbapenem-resistant Enterobacterales |b results from a prospective, multinational case-control-control matched cohorts study (EURECA) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: To assess the mortality attributable to infections caused by carbapenem-resistant Enterobacterales (CRE) and to investigate the effect of clinical management on differences in observed outcomes in a multinational matched cohort study | ||
| 520 | |a METHODS: A prospective matched-cohorts study (NCT02709408) was performed in 50 European hospitals from March 2016 to November 2018. The main outcome was 30-day mortality with an active post-discharge follow-up when applied. The CRE cohort included patients with complicated urinary tract infections, complicated intra-abdominal infections, pneumonia, or bacteraemia from other sources because of CRE. Two control cohorts were selected: patients with infection caused by carbapenem-susceptible Enterobacterales (CSE) and patients without infection. Matching criteria included type of infection for the CSE group, hospital ward of CRE detection, and duration of hospital admission up to CRE detection. Multivariable and stratified Cox regression was applied | ||
| 520 | |a RESULTS: The cohorts included 235 patients with CRE infection, 235 patients with CSE infection, and 705 non-infected patients. The 30-day mortality (95% CI) was 23.8% (18.8-29.6), 10.6% (7.2-15.2), and 8.4% (6.5-10.6), respectively. The difference in 30-day mortality rates between patients with CRE infection when compared with patients with CSE infection was 13.2% (95% CI, 6.3-20.0), (HR, 2.57; 95% CI, 1.55-4.26; p < 0.001), and 15.4% (95% CI, 10.5-20.2) when compared with non-infected patients (HR, 3.85; 95% CI, 2.57-5.77; p < 0.001). The population attributable fraction for 30-day mortality for CRE vs. CSE was 19.28%, and for CRE vs. non-infected patients was 9.61%. After adjustment for baseline variables, the HRs for mortality were 1.87 (95% CI, 0.99-3.50; p 0.06) and 3.65 (95% CI, 2.29-5.82; p < 0.001), respectively. However, when treatment-related time-dependent variables were added, the HR of CRE vs. CSE reduced to 1.44 (95% CI, 0.78-2.67; p 0.24) | ||
| 520 | |a DISCUSSION: CRE infections are associated with significant attributable mortality and increased adjusted hazard of mortality when compared with CSE infections or patients without infection. Underlying patient characteristics and a delay in appropriate treatment play an important role in the CRE mortality | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antimicrobial resistance | |
| 650 | 4 | |a Carbapenem-resistant Enterobacterales | |
| 650 | 4 | |a KPC | |
| 650 | 4 | |a Metallo-β-lactamases | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a OXA | |
| 650 | 7 | |a Carbapenems |2 NLM | |
| 700 | 1 | |a Bravo-Ferrer, Jose M |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Galera, Salvador |e verfasserin |4 aut | |
| 700 | 1 | |a Kostyanev, Tomislav |e verfasserin |4 aut | |
| 700 | 1 | |a de Kraker, Marlieke E A |e verfasserin |4 aut | |
| 700 | 1 | |a Feifel, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Palacios-Baena, Zaira R |e verfasserin |4 aut | |
| 700 | 1 | |a Schotsman, Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Cantón, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Daikos, George L |e verfasserin |4 aut | |
| 700 | 1 | |a Carevic, Biljana |e verfasserin |4 aut | |
| 700 | 1 | |a Dragovac, Gorana |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Lionel K |e verfasserin |4 aut | |
| 700 | 1 | |a Raka, Lul |e verfasserin |4 aut | |
| 700 | 1 | |a Hristea, Adriana |e verfasserin |4 aut | |
| 700 | 1 | |a Viale, Pierluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Akova, Murat |e verfasserin |4 aut | |
| 700 | 1 | |a Cano, Ángela |e verfasserin |4 aut | |
| 700 | 1 | |a Reguera, Jose María |e verfasserin |4 aut | |
| 700 | 1 | |a Bartoloni, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Florescu, Simin-Aysel |e verfasserin |4 aut | |
| 700 | 1 | |a Benea, Serban |e verfasserin |4 aut | |
| 700 | 1 | |a Bukarica, Ljiljana |e verfasserin |4 aut | |
| 700 | 1 | |a Asensio, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Korten, Volkan |e verfasserin |4 aut | |
| 700 | 1 | |a Grundmann, Hajo |e verfasserin |4 aut | |
| 700 | 1 | |a Goossens, Herman |e verfasserin |4 aut | |
| 700 | 1 | |a Bonten, Marc J |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Gutiérrez, Belén |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Baño, Jesús |e verfasserin |4 aut | |
| 700 | 0 | |a COMBACTE-CARE-EURECA team |e verfasserin |4 aut | |
| 700 | 1 | |a Serna, Almudena de la |e investigator |4 oth | |
| 700 | 1 | |a Monteau, Sophie |e investigator |4 oth | |
| 700 | 1 | |a Palomo, Virginia |e investigator |4 oth | |
| 700 | 1 | |a Soriano, Elena |e investigator |4 oth | |
| 700 | 1 | |a Gutierrez, David |e investigator |4 oth | |
| 700 | 1 | |a Moreno, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Sojo-Dorado, Jesus |e investigator |4 oth | |
| 700 | 1 | |a Morales, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Maldonado, Natalia |e investigator |4 oth | |
| 700 | 1 | |a Santis, Lucia Valiente de |e investigator |4 oth | |
| 700 | 1 | |a Ciezar, Antonio Plata |e investigator |4 oth | |
| 700 | 1 | |a Ruiz Mesa, Juan Diego |e investigator |4 oth | |
| 700 | 1 | |a Diaz, Beatriz Sobrino |e investigator |4 oth | |
| 700 | 1 | |a Gomez, Ignacio Marquez |e investigator |4 oth | |
| 700 | 1 | |a Camacho, Ines Perez |e investigator |4 oth | |
| 700 | 1 | |a Cano, Angela |e investigator |4 oth | |
| 700 | 1 | |a Frutos-Adame, Azahara |e investigator |4 oth | |
| 700 | 1 | |a Guzman-Puche, Julia |e investigator |4 oth | |
| 700 | 1 | |a Gracia-Ahufinger, Irene |e investigator |4 oth | |
| 700 | 1 | |a Perez-Nadales, Elena |e investigator |4 oth | |
| 700 | 1 | |a Torre-Gimenez, Julian |e investigator |4 oth | |
| 700 | 1 | |a Pyrpasopoulou, Athina |e investigator |4 oth | |
| 700 | 1 | |a Iosifidis, Elias |e investigator |4 oth | |
| 700 | 1 | |a Chorafa, Elsa |e investigator |4 oth | |
| 700 | 1 | |a Radovanovic, Ivana |e investigator |4 oth | |
| 700 | 1 | |a Petrovic, Sladjana |e investigator |4 oth | |
| 700 | 1 | |a Cvetkovi, Slavica |e investigator |4 oth | |
| 700 | 1 | |a Melentijevic, Srdjan-Sanja |e investigator |4 oth | |
| 700 | 1 | |a Bicmen, Can |e investigator |4 oth | |
| 700 | 1 | |a Senol, Gunes |e investigator |4 oth | |
| 700 | 1 | |a Tubau, Fe |e investigator |4 oth | |
| 700 | 1 | |a Camara, Jordi |e investigator |4 oth | |
| 700 | 1 | |a Daniel Gumucio, Victor |e investigator |4 oth | |
| 700 | 1 | |a Bassoulis, Dimitris |e investigator |4 oth | |
| 700 | 1 | |a Deliolanis, John |e investigator |4 oth | |
| 700 | 1 | |a Pitiriga, Vassiliki Ch |e investigator |4 oth | |
| 700 | 1 | |a Triarides, Nikolaos |e investigator |4 oth | |
| 700 | 1 | |a Argiti, Efstathia |e investigator |4 oth | |
| 700 | 1 | |a Legakis, Nikolaos J |e investigator |4 oth | |
| 700 | 1 | |a Margarita, Kyriakidou |e investigator |4 oth | |
| 700 | 1 | |a Gijón-Cordero, Desirée |e investigator |4 oth | |
| 700 | 1 | |a Ruiz-Garbajosa, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Rossolini, Gian Maria |e investigator |4 oth | |
| 700 | 1 | |a Nica, Maria |e investigator |4 oth | |
| 700 | 1 | |a Talapan, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Medić, Deana |e investigator |4 oth | |
| 700 | 1 | |a Prijić, Sanja Maričić |e investigator |4 oth | |
| 700 | 1 | |a Caballero, Mireia Cantero |e investigator |4 oth | |
| 700 | 1 | |a Ramírez, Lina M Parra |e investigator |4 oth | |
| 700 | 1 | |a Bilgin, Hüseyin |e investigator |4 oth | |
| 700 | 1 | |a Dalekos, George N |e investigator |4 oth | |
| 700 | 1 | |a Stefos, Aggelos |e investigator |4 oth | |
| 700 | 1 | |a Spyridis, Nikolaos |e investigator |4 oth | |
| 700 | 1 | |a Michos, Athanasios |e investigator |4 oth | |
| 700 | 1 | |a De Rosa, Francesco Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Cavallo, Rossana |e investigator |4 oth | |
| 700 | 1 | |a Petrosillo, Nicola |e investigator |4 oth | |
| 700 | 1 | |a Dicaro, Antonio |e investigator |4 oth | |
| 700 | 1 | |a Landini, Maria Paola |e investigator |4 oth | |
| 700 | 1 | |a Degli Atti, Marta Luisa Ciofi |e investigator |4 oth | |
| 700 | 1 | |a Masanovic, Mileva |e investigator |4 oth | |
| 700 | 1 | |a Matkovic, Dusan |e investigator |4 oth | |
| 700 | 1 | |a Tsiodras, Sotirios |e investigator |4 oth | |
| 700 | 1 | |a Blasi, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Pasquale, Marta Di |e investigator |4 oth | |
| 700 | 1 | |a Viscoli, Claudio |e investigator |4 oth | |
| 700 | 1 | |a Vata, Andrei |e investigator |4 oth | |
| 700 | 1 | |a Dorneanu, Olivia |e investigator |4 oth | |
| 700 | 1 | |a Kapisyzi, Perlat |e investigator |4 oth | |
| 700 | 1 | |a Vince, Adriana |e investigator |4 oth | |
| 700 | 1 | |a Tsigou, Evdoxia |e investigator |4 oth | |
| 700 | 1 | |a Maltezos, Efstratios |e investigator |4 oth | |
| 700 | 1 | |a Komnos, Apostolos |e investigator |4 oth | |
| 700 | 1 | |a Gogos, Charalampos |e investigator |4 oth | |
| 700 | 1 | |a Franzetti, Fabio |e investigator |4 oth | |
| 700 | 1 | |a De Rosa, Francesco Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Antonelli, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Lupse, Mihaela |e investigator |4 oth | |
| 700 | 1 | |a Corneci, Dan |e investigator |4 oth | |
| 700 | 1 | |a Tomescu, Dana |e investigator |4 oth | |
| 700 | 1 | |a Georgescu, Anca |e investigator |4 oth | |
| 700 | 1 | |a Bukarica, Ljiljana |e investigator |4 oth | |
| 700 | 1 | |a Mitrović, Goran |e investigator |4 oth | |
| 700 | 1 | |a Krstić, Nataša Lukić |e investigator |4 oth | |
| 700 | 1 | |a Kurti, Arsim |e investigator |4 oth | |
| 700 | 1 | |a Reuter, Sandra |e investigator |4 oth | |
| 700 | 1 | |a Díaz-Pollán, Beatriz |e investigator |4 oth | |
| 700 | 1 | |a Sabater, Julia Origüen |e investigator |4 oth | |
| 700 | 1 | |a Muñoz, Patricia |e investigator |4 oth | |
| 700 | 1 | |a Azap, Alpay |e investigator |4 oth | |
| 700 | 1 | |a Ancak, Banu |e investigator |4 oth | |
| 700 | 1 | |a Sahin, Arife |e investigator |4 oth | |
| 700 | 1 | |a Akalin, Halis |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 30(2024), 2 vom: 01. Jan., Seite 223-230 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:30 |g year:2024 |g number:2 |g day:01 |g month:01 |g pages:223-230 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2023.11.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 30 |j 2024 |e 2 |b 01 |c 01 |h 223-230 | ||